Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6483.0000 -55.00 (-0.84%)
NSE May 23, 2025 15:31 PM
Volume: 224.1K
 

6483.00
-0.84%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 24.6% YoY to | 1008.1 crore (I-direct estimate: | 932.6 crore) due to ~26% growth in generic business to | 501 crore and ~22% growth in custom synthesis (CS) business to | 443 crore EBITDA margins increased 273 bps YoY to 40% (I-direct estimate: 37%) mainly due to a better product mix. EBITDA increased ~34% YoY to | 403.8 crore (I-direct estimate: | 345.1 crore) Net profit witnessed YoY increase of ~23% to | 301.8 crore (I-direct...
Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.
More from Divi's Laboratories Ltd.
Recommended